Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
SERTRALINE HYDROCHLORIDE
Niche Generics Limited
50 Milligram
Film Coated Tablet
2005-08-05
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SertraNiche 50 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 50 mg sertraline (as sertraline hydrochloride). For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet White, oval, slightly biconvex film-coated tablet with score on one side and “S3” sign on the opposite side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Major depressive episodes. Prevention of recurrence of major depressive episodes. Panic disorder, with or without agoraphobia. Obsessive compulsive disorder (OCD) in adults and paediatric patients aged 6-17 years. Social anxiety disorder. Post traumatic stress disorder (PTSD) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION SertraNiche should be administered once daily, either in the morning or evening. SertraNiche tablet can be administered with or without food _Initial treatment_ _Depression and OCD_ Sertraline treatment should be started at a dose of 50 mg/day. _Panic Disorder, PTSD, and Social Anxiety Disorder_ Therapy should be initiated at 25 mg/day. After one week, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side effects characteristic of panic disorder. _Titration_ _Depression, OCD, Panic Disorder, Social Anxiety Disorder and PTSD_ Patients not responding to a 50 mg dose may benefit from dose increases. Dose changes should be made in steps of 50 mg at intervals of at least one week, up to a maximum of 200 mg/day. Changes in dose should not be made more frequently than once per week given the 24-hour elimination half life of sertraline. The onset of therapeutic effec Läs hela dokumentet